Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borreb...

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

Novo Nordisk to invest billions in new quality control lab

Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.

The first pharmaceutical for eosinophilic esophagitis approved in the U.S.

The U.S. Drug Administration has approved the drug Dupixent (dupilumab) to treat inflammation of the oesophagus of the type eosinophil esophagitis.

Rekordstor donation till cancerforskning i Lund – ”Once in a lifetime-möjlighet”

Lunds universitet får den största donationen i lärosätets moderna historia, enligt ett pressmeddelande.

Truly Labs AB

Standardisation in automation

B. Braun Melsungen had a great idea and implemented it throughout the plant. Production for infusion solutions was to be largely standardised. B. Braun hoped th...

RegSmart Life Science AB

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

Aurevia

NorthX Biologics Matfors AB

"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which...

Save the dates: ZEISS Quality Innovation Summit, October 22-24

Embark on a journey to the future of metrology.

Assignment: Facilitate the retention of foreign researchers

A newly appointed public inquiry is to develop measures to make attracting and retaining foreign doctoral students and researchers in Sweden easier.

TECHNIA AB

He saved lives with his theories – was ostracised and ended up in a mental hospital

Hungarian doctor Ignaz Semmelweis (1818-1865) undoubtedly possessed plenty of persistence, diligence and sound reasoning skills – but he was hardly blessed with...

PharmaRelations AB

BMS satsar på CAR-T-terapi direkt i kroppen

Läkemedelsjätten Bristol Myers Squibb fyller på sin portfölj inom CAR-T-området genom att förvärva biotechbolaget Orbital Therapeutics för 1,5 miljarder dollar,...

Varningar om Millennium ignorerades

”Som att hälla flytande cement i organisationen.” Så beskriver IT-professorn Johan Magnusson det hårt kritiserade journalsystemet Millennium. Efter flera turer ...

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Kompauto Nordic AB

Bioarctic om TLV-analysen: ”Mycket märklig bedömning”

Bioarctic håller inte med om TLV:s hälsoekonomiska analys av bolagets alzheimerläkemedel Leqembi. ”Deras beräkningar innehåller en hel del antaganden som förefa...